IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by CX Institutional

CX Institutional lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 25.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,176 shares of the medical research company’s stock after selling 395 shares during the quarter. CX Institutional’s holdings in IQVIA were worth $231,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. FMR LLC boosted its holdings in shares of IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after acquiring an additional 804,963 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after acquiring an additional 583,396 shares during the period. Impax Asset Management Group plc boosted its holdings in shares of IQVIA by 9.7% during the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after acquiring an additional 157,809 shares during the period. Legal & General Group Plc boosted its holdings in shares of IQVIA by 0.8% during the second quarter. Legal & General Group Plc now owns 1,514,237 shares of the medical research company’s stock valued at $320,170,000 after acquiring an additional 11,715 shares during the period. Finally, Nordea Investment Management AB boosted its holdings in shares of IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on IQV. Morgan Stanley cut their price objective on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. The Goldman Sachs Group cut their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Evercore ISI cut their price objective on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Finally, BTIG Research cut their price objective on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $255.71.

IQVIA Trading Down 0.7 %

Shares of IQV opened at $204.54 on Monday. The business’s 50-day moving average price is $199.71 and its 200 day moving average price is $221.11. The stock has a market capitalization of $37.12 billion, a P/E ratio of 26.84, a P/E/G ratio of 2.14 and a beta of 1.48. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.